Pregled bibliografske jedinice broj: 914781
Clinical and histopathological characteristics of HER2-positive breast cancer in patients treated with adjuvant trastuzumab
Clinical and histopathological characteristics of HER2-positive breast cancer in patients treated with adjuvant trastuzumab // European Journal of Cancer, Volume 50, Supplement 5, July 2014
München, Njemačka, 2014. str. 179-179 doi:10.1016/S0959-8049(14)50654-5 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 914781 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Clinical and histopathological characteristics of HER2-positive breast cancer in patients treated with adjuvant trastuzumab
Autori
Jurčić, Petra
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
European Journal of Cancer, Volume 50, Supplement 5, July 2014
/ - , 2014, 179-179
Skup
23rd Biennial Congress of the European Association for Cancer Research
Mjesto i datum
München, Njemačka, 05.07.2014. - 08.07.2014
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Breast cancer ; trastuzumab ; outcome
Sažetak
The outcome of trastuzumab therapy cannot be predicted based on the histopathological characteristics of cancer. In adjuvant trastuzumab therapy, outcomes for HER2-positive and for ER-positive, HER2-negative breast cancer are similar. The focus in the future sholud be on improving the treatment of hormone-receptor negative, HER2 positive tumors.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
